<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.business-standard.com/article/pti-stories/ajanta-pharma-q2-net-dips-7-pc-to-rs-116-crore-119110501638_1.html"/>
    <meta property="og:site_name" content="Business-Standard"/>
    <meta property="article:published_time" content="2019-11-05T15:05:00+00:00"/>
    <meta property="og:title" content="Ajanta Pharma Q2 net profit dips 7% to Rs 116 crore; stock ends flat"/>
    <meta property="og:description" content="Income from operations rose to Rs 643 crore during the period under review, as compared with Rs 544 crore in the year-ago period"/>
  </head>
  <body>
    <article>
      <h1>Ajanta Pharma Q2 net profit dips 7% to Rs 116 crore; stock ends flat</h1>
      <h2>Income from operations rose to Rs 643 crore during the period under review, as compared with Rs 544 crore in the year-ago period</h2>
      <address><time datetime="2019-11-05T15:05:00+00:00">05 Nov 2019, 15:05</time> by <a rel="author">Press Trust of India</a></address>
      <p>Drug firm <a href="https://www.business-standard.com/topic/ajanta-pharma">Ajanta Pharma </a>on Tuesday reported 7 per cent decline in net profit at Rs 116 crore for the second quarter ended September 30.</p>
      <p>The company had posted a net profit of Rs 125 crore in the same period of previous fiscal.</p>
      <p>Income from operations, however, rose to Rs 643 crore during the period under review, as compared with Rs 544 crore in the year-ago period, <a href="https://www.business-standard.com/topic/ajanta-pharma">Ajanta Pharma </a>said in a regulatory filing.</p>
      <p>Shares of the company on Tuesday ended 0.20 per cent down at Rs 1,002.40 apiece on the BSE.</p>
    </article>
  </body>
</html>